retatrutide clinical trials phase ESC 2024: improves lipid and cardiovascular risk profile in II trial Phase III retatrutide study demonstrates

Description Retatrutide is an advanced triple-agonist peptide developed by Eli Lilly that simultaneously activates the GLP-1, GIP, and glucagon receptors

Metformin is a valuable treatment option for women with PCOS, and it can help them manage their weight and increase their chances of becoming pregnant

Clinical Takeaway Genetics loads the gun

It plays a role through a specific GLP-1 receptor (GLP-1R) distributed in many organs or tissues and participates in the regulation of glucose homeostasis in the body

However, its important to note that both Semaglutide GLP-1 and Liraglutide can cause gastrointestinal side effects, with a slightly higher incidence in patients taking Semaglutide GLP-1

Predictors of weight-loss response with glucagon-like peptide-1 receptor agonist treatment among adolescents with severe obesity